Bottom Line:
📊 HOLD - EXTENDED: LLY is 7.5% above its trading range ($1085.57). Fundamentals are solid but entry is stretched. Hold existing positions; wait for pullback to add new shares.
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)50% (Hyper Growth)
EST. PRICE IN 2031
$2071.36
Based on 13.5% avg growth
INTRINSIC VALUE TODAY
$1286.15
9.3% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 25.0x Exit PE.
Valuation Analysis: LLY is currently trading at $1166.54, which is considered extended relative to its 30-day fair value range of $937.82 to $1085.57. The stock's valuation (Forward PE: 25.4) is in line with its historical norms (26.2). Remarkably, the market is currently pricing in an annual earnings decline of 1.0% over the next few years. This pessimistic expectation contrasts with the company's recent 169.9% earnings growth, suggesting potential undervaluation if the company simply maintains stability.
Technical Outlook: Technically, LLY is in a downtrend. The price is approaching resistance at $1166.29. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 3.1% recently.
Market Sentiment: LLY has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$937.82 -
$1085.57
Company Quality Score
59/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
57.1%
Protect Your Profits
LLY is technically overbought (RSI 72). Consider hedging now to protect against a potential pullback while keeping your upside.
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.